Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
study ends around

Description

Summary

This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

Official Title

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2Bio) Gene Therapy (GT) Products

Details

This is a long-term follow-up study designed to evaluate delayed safety events and long-term efficacy of A2 Bio GT products for participants who received any amount of A2 Bio GT products in a previous interventional study. No further interventional treatment is administered in this study.

Participants will enroll in this long-term follow-up study upon completion of 2 years of follow-up in the assigned interventional study in which they received treatment. Participants will be followed for up to 15 years after administration of A2 Bio GT product. This study will collect long-term safety and efficacy data as outlined by the FDA guidance for long-term follow-up for GT products.

Keywords

Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC), Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Pancreatic Cancer, NSCLC, Mesothelioma, Ovarian Cancer, Ovarian Carcinoma, Head and Neck (HNSCC), Head and Neck Cancer, Renal Cell Carcinoma (Kidney Cancer), Triple Negative Breast Cancer (TNBC), CAR T Cell Therapy, Gene Therapy, Colorectal Neoplasms, Non-Small-Cell Lung Carcinoma, Small Cell Lung Carcinoma, Pancreatic Neoplasms, Ovarian Neoplasms, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Renal Cell Carcinoma, Kidney Neoplasms, Triple Negative Breast Neoplasms, No additional intervention administered in this long term follow-up study

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
  2. Able to provide written informed consent for this long-term follow-up study
  3. Able to comply with study requirements

You CAN'T join if...

  1. There are no specific exclusion criteria for this study

Locations

  • UCLA Medical Center
    Los Angeles California 90404 United States
  • UCSD Moores Cancer Center
    La Jolla California 92093 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
A2 Biotherapeutics Inc.
Links
A2 Bio Website Sign up for this study
ID
NCT06885424
Study Type
Observational
Participants
Expecting 400 study participants
Last Updated